Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Danshen Dripping Pill in Diabetic Microvascular Angina
NCT06727890Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in microvascular angina (MVA) comparing Compound Danshen Dripping Pill with Placebo (2 arms). Primary endpoint: Changes of coronary flow reserve at 12 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
Compound Danshen
03
Conditions
microvascular angina (MVA)
Beyond the preview
Go deeper on NCT06727890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727890.